セッション

検索結果は4件です。

IF4a-1 A Comparison of Viral Hepatitis A (HAV) and E (HEV) in the United States and Asia
Kenrad E. Nelson(Johns Hopkins UniversityUSA)
Acute HEV in the USA decreased 93.70/o from 1990 (14/100000) to 2009 (O.6/100000). HAV vaccine wasrecom血ended for high risk persons(1996)all chilldren in high incidence areas(1999)and all children at1...

第98回日本消化器病学会総会

IF4a-2 Viral Hepatitis A and E in Japan
Yoko Tamada(Clinical Research CenterNational Hospital Organization(NHO)Nagasaki Medical CenterJapan)
Objective :To examine recent trends of hepatitis A (AHA) and hepatitis E (AHE) in Japan.Methods :During 1980 through 2010sentinel surve皿ance was conducted in 31 national hospitals in a prospective co-...

第98回日本消化器病学会総会

IF4a-3 Culture Systems for HEV
Hiroaki Okamoto(Division of VirologyDepartment of Infection and ImmunityJichi Medical University School of MedicineJapan)
Early studies reported the propagation of hepatitis E virus (HEV) in either primary hepatocytes or severalestablishe・d cell linesbut replication was inefficient. Recentlyefficient culture systems have...

第98回日本消化器病学会総会

IF4a-4 HEV Vaccine Strategies : Utility and Prospect
James Wai Kuo Shih(National Institute of Diagnostics and Vaccine DevelopmentSchool of Public HealthXiamen UniversityChina)
The hepatitis E vaccineHEV239(Hecolin)w皿be commercially available in China in 2012The vaccinehas been shown in a 1arge Phase III clinical trial to be well tolerated by adults and confer 1000/o protect...

第98回日本消化器病学会総会